Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)

NCT04140305 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT04140305
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04140305 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Terminated
Start date
January 16, 2020
Completion date
May 15, 2025
Enrollment
188 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis